The glycemia risk index (GRI) is a novel composite continuous glucose monitoring (CGM) metric composed of hypoglycemia and hyperglycemia components and is weighted toward extremes. This study aimed to investigate the association between GRI and the risk of albuminuria in type 1 diabetes.
Methods:
The 90-day CGM tracings of 330 individuals with type 1 diabetes were included in the analysis. Glycemia risk index was divided into five risk zones (A-E), and hypoglycemia and hyperglycemia components were divided into quintiles. Albuminuria was defined as a spot urine albumin-to-creatinine ratio ≥30 mg/g. Associations of albuminuria with GRI and its hypoglycemia and hyperglycemia components were estimated.
Results:
Mean GRI and glycated hemoglobin (HbA1c) were 40.9 ± 21.3 and 7.3 ± 1.0%, respectively, and the overall prevalence of albuminuria was 17.6%. Prevalence of albuminuria differed significantly by GRI zone (P = .023). In logistic regression analysis, the adjusted odds ratio (OR) of albuminuria per increase in the GRI zone was 1.70 (95% confidence interval [CI]: 1.19-2.41) after adjusting for various factors affecting albuminuria. The association remained significant after adjusting for achievement of the recommended target of time in range (70-180 mg/dL; >70%) or HbA1c (<7%). The hyperglycemia component of GRI was also associated with albuminuria, and the association remained significant even after adjusting for HbA1c level itself (adjusted OR 1.44, 95% CI: 1.05-1.98).
Conclusions:
Glycemia risk index is significantly associated with albuminuria in individuals with type 1 diabetes.
American Diabetes Association Professional Practice Committee. 7. Diabetes technology: standards of care in diabetes—2024. Diabetes Care. 2023;47:S126-S144.
2.
ChoiJHLeeKAMoonJH, et al. 2023 Clinical practice guidelines for diabetes mellitus of the Korean Diabetes Association. Diabetes Metab J. 2023;47(5):575-594.
3.
BeckRWRiddlesworthTRuedyK, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA. 2017;317:371-378.
4.
LindMPolonskyWHirschIB, et al. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. JAMA. 2017;317:379-387.
5.
TumminiaACrimiSSciaccaL, et al. Efficacy of real-time continuous glucose monitoring on glycaemic control and glucose variability in type 1 diabetic patients treated with either insulin pumps or multiple insulin injection therapy: a randomized controlled crossover trial. Diabetes Metab Res Rev. 2015;31(1):61-68.
6.
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group; TamborlaneWVBeckRWBodeBW, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008;359:1464-1476.
7.
BattelinoTCongetIOlsenB, et al. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia. 2012;55(12):3155-3162.
8.
DeissDBolinderJRivelineJP, et al. Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring. Diabetes Care. 2006;29(12):2730-2732.
9.
O’ConnellMADonathSO’NealDN, et al. Glycaemic impact of patient-led use of sensor-guided pump therapy in type 1 diabetes: a randomised controlled trial. Diabetologia. 2009;52(7):1250-1257.
10.
BolinderJAntunaRGeelhoed-DuijvestijnP, et al. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet. 2016;388:2254-2263.
11.
HermannsNSchumannBKulzerBHaakT. The impact of continuous glucose monitoring on low interstitial glucose values and low blood glucose values assessed by point-of-care blood glucose meters: results of a crossover trial. J Diabetes Sci Technol. 2014;8(3):516-522.
12.
van BeersCADeVriesJHKleijerSJ, et al. Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial. Lancet Diabetes Endocrinol. 2016;4(11):893-902.
13.
HeinemannLFreckmannGEhrmannD, et al. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial. Lancet. 2018;391:1367-1377.
14.
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group; BeckRWHirschIBLaffelL, et al. The effect of continuous glucose monitoring in well-controlled type 1 diabetes. Diabetes Care. 2009;32(8):1378-1383.
15.
BattelinoTPhillipMBratinaN, et al. Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes. Diabetes Care. 2011;34:795-800.
16.
Seyed AhmadiSWestmanKPivodicA, et al. The association between HbA1c and time in hypoglycemia during CGM and self-monitoring of blood glucose in people with type 1 diabetes and multiple daily insulin injections: a randomized clinical trial (GOLD-4). Diabetes Care. 2020;43(9):2017-2024.
17.
KimJYJinSMSimKH, et al. Continuous glucose monitoring with structured education in adults with type 2 diabetes managed by multiple daily insulin injections: a multicentre randomised controlled trial. Diabetologia. 2024;67(7):1223-1234.
18.
YooJHKimJH. Advances in continuous glucose monitoring and integrated devices for management of diabetes with insulin-based therapy: improvement in glycemic control. Diabetes Metab J. 2023;47(1):27-41.
19.
YuJLeeSHKimMK. Recent updates to clinical practice guidelines for diabetes mellitus. Endocrinol Metab (Seoul). 2022;37(1):26-37.
20.
KlonoffDCWangJRodbardD, et al. A glycemia risk index (GRI) of hypoglycemia and hyperglycemia for continuous glucose monitoring validated by clinician ratings. J Diabetes Sci Technol. 2023;17(5):1226-1242.
21.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) group. Lancet. 1998;352:837-853.
22.
Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group; Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002;287:2563-2569.
23.
KimJYKimNH. Initial combination therapy in type 2 diabetes. Endocrinol Metab (Seoul). 2024;39:23-32.
24.
KimKI. Risk stratification of cardiovascular disease according to age groups in new prevention guidelines: a review. J Lipid Atheroscler. 2023;12(2):96-105.
25.
KimNHSeoMHJungJHHanKDKimMKKimNH. 2023 Diabetic kidney disease fact sheet in Korea. Diabetes Metab J. 2024;48(3):463-472.
26.
AndersHJHuberTBIsermannBSchifferM. CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease. Nat Rev Nephrol. 2018;14(6):361-377.
27.
BaekJHLeeWJLeeBW, et al. Age at diagnosis and the risk of diabetic nephropathy in young patients with type 1 diabetes mellitus. Diabetes Metab J. 2021;45:46-54.
28.
LeelarathnaLThabitHWilinskaME, et al. Evaluating glucose control with a novel composite continuous glucose monitoring index. J Diabetes Sci Technol. 2020;14(2):277-283.
29.
YooJHChoiMSAhnJ, et al. Association between continuous glucose monitoring-derived time in range, other core metrics, and albuminuria in type 2 diabetes. Diabetes Technol Ther. 2020;22(10):768-776.
30.
FlyvbjergADagnaes-HansenFDe VrieseASSchrijversBFTiltonRGRaschR. Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes. 2002;51(10):3090-3094.
31.
MoriwakiYYamamotoTShibutaniY, et al. Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. Metabolism. 2003;52(5):605-608.
32.
SusztakKRaffACSchifferMBöttingerEP. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes. 2006;55(1):225-233.
33.
RheeSYKimYS. The role of advanced glycation end products in diabetic vascular complications. Diabetes Metab J. 2018;42:188-195.
34.
CederholmJEliassonBNilssonPMWeissLGudbjörnsdottirS; Steering Committee of the Swedish National Diabetes Register. Microalbuminuria and risk factors in type 1 and type 2 diabetic patients. Diabetes Res Clin Pract. 2005;67(3):258-266.
35.
VargheseJSHoJCAnjanaRM, et al. Profiles of intraday glucose in type 2 diabetes and their association with complications: an analysis of continuous glucose monitoring data. Diabetes Technol Ther. 2021;23(8):555-564.
36.
YunJSKoSHKoSH, et al. Presence of macroalbuminuria predicts severe hypoglycemia in patients with type 2 diabetes: a 10-year follow-up study. Diabetes Care. 2013;36(5):1283-1289.
37.
JafriRZBalliroCAEl-KhatibF, et al. A three-way accuracy comparison of the Dexcom G5, Abbott Freestyle Libre Pro, and Senseonics Eversense continuous glucose monitoring devices in a home-use study of subjects with type 1 diabetes. Diabetes Technol Ther. 2020;22(11):846-852.
38.
KrolewskiASLaffelLMKrolewskiM, et al. Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med. 1995;332:1251-1255.
39.
HuangXZhouYXuB, et al. Glycated haemoglobin A1c is associated with low-grade albuminuria in Chinese adults. BMJ Open. 2015;5:e007429.
40.
LianHWuHNingJ, et al. The risk threshold for hemoglobin A1c associated with albuminuria: a population-based study in China. Front Endocrinol (Lausanne). 2021;12:673976.
41.
American Diabetes Association Professional Practice Committee; 6. Glycemic goals and hypoglycemia: standards of care in diabetes—2024. Diabetes Care. 2023;47:S111-S125.
42.
KompalaTWongJNeinsteinA. Diabetes specialists value continuous glucose monitoring despite challenges in prescribing and data review process. J Diabetes Sci Technol. 2023;17(5):1265-1273.
43.
HoogendoornCJHernandezRSchneiderS, et al. Glycemic risk index profiles and predictors among diverse adults with type 1 diabetes. J Diabetes Sci Technol. 2024;18(5):1070-1078.
44.
YooJHKimJH. Time in range from continuous glucose monitoring: a novel metric for glycemic control. Diabetes Metab J. 2021;45:795.
45.
RanjanAGRosenlundSVHansenTWRossingPAndersenSNørgaardK. Improved time in range over 1 year is associated with reduced albuminuria in individuals with sensor-augmented insulin pump-treated type 1 diabetes. Diabetes Care. 2020;43(11):2882-2885.
46.
KimJYYooJHKimJH. Comparison of glycemia risk index with time in range for assessing glycemic quality. Diabetes Technol Ther. 2023;25(12):883-892.
47.
YooJHKimJYKimJH. Association between continuous glucose monitoring-derived glycemia risk index and albuminuria in type 2 diabetes. Diabetes Technol Ther. 2023;25(10):726-735.
48.
WangYLuJNiJ, et al. Association between glycaemia risk index (GRI) and diabetic retinopathy in type 2 diabetes: a cohort study. Diabetes Obes Metab. 2023;25(9):2457-2463.
49.
HoganSLVupputuriSGuoX, et al. Association of cigarette smoking with albuminuria in the United States: the third national health and nutrition examination survey. Ren Fail. 2007;29(2):133-142.
50.
KarDGilliesCNathMKhuntiKDaviesMJSeiduS. Association of smoking and cardiometabolic parameters with albuminuria in people with type 2 diabetes mellitus: a systematic review and meta-analysis. Acta Diabetol. 2019;56(8):839-850.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
